midomafetamine (MDMA) / Lykos Therapeutics  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
midomafetamine (MDMA) / Multidisciplinary Association for Psychedelic Studies (MAPS)
NCT06189027: Epigenetics and MDMA-Assisted Psychotherapy for PTSD

Active, not recruiting
3
45
US
MDMA, Psychotherapy
University of Southern California, Multidisciplinary Association for Psychedelic Studies
PTSD
11/23
12/24
NCT03537014: A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP1)

Completed
3
100
Canada, US, RoW
Therapy, Manualized therapy, Midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA, Placebo, Inactive placebo
Lykos Therapeutics
Posttraumatic Stress Disorder
08/20
08/20
NCT04077437: A Multi-Site Phase 3 Study of MDMA-Assisted Psychotherapy for PTSD (MAPP2)

Completed
3
121
US, RoW
Therapy, Manualized MDMA-assisted therapy, Midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA, Placebo, Inactive placebo
Lykos Therapeutics
Posttraumatic Stress Disorder
10/22
11/22
MAPPUSX, NCT04714359: A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD

Completed
3
85
Canada, US, RoW
Midomafetamine, 3,4-methylenedioxymethamphetamine, MDMA
Lykos Therapeutics
PTSD
11/23
11/23

Download Options